{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:08:44Z","timestamp":1789117724690,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004702","name":"Baxter International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03762-6","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:42:10Z","timestamp":1789116130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics of Medicare and Medicaid Patients Initiating Volara Respiratory Therapy: A Medical Claims Study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6927-4454","authenticated-orcid":false,"given":"Wendy M.","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6123-6947","authenticated-orcid":false,"given":"Suhui Evelyn","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn M.","family":"Klabnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley H.","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwen M.","family":"Warling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Lechtzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2383-5716","authenticated-orcid":false,"given":"Michael J.","family":"Barna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"3762_CR1","unstructured":"Baxter. The Volara System: oscillation and lung expansion therapy (OLE). https:\/\/www.hillrom.com\/en\/products\/volara-acute-care\/. Accessed 2026 Apr 27."},{"issue":"6","key":"3762_CR2","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1513\/AnnalsATS.201509-597OC","volume":"13","author":"N Lechtzin","year":"2016","unstructured":"Lechtzin N, Wolfe LF, Frick KD. The impact of high-frequency chest wall oscillation on healthcare use in patients with neuromuscular diseases. Ann Am Thorac Soc. 2016;13(6):904\u20139.","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"3762_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jamcollsurg.2019.06.004","volume":"229","author":"TT Huynh","year":"2019","unstructured":"Huynh TT, Liesching TN, Cereda M, et al. Efficacy of oscillation and lung expansion in reducing postoperative pulmonary complication. J Am Coll Surg. 2019;229(5):458\u201366.","journal-title":"J Am Coll Surg"},{"key":"3762_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.chpulm.2023.100013","author":"M Camacho Urribarri","year":"2023","unstructured":"Camacho Urribarri M, Becker B, Murray A. Impact of high-frequency chest wall oscillation on health care resource use and economic outcomes in adult patients with non-cystic fibrosis bronchiectasis in the United States. CHEST Pulm. 2023. https:\/\/doi.org\/10.1016\/j.chpulm.2023.100013.","journal-title":"CHEST Pulm"},{"key":"3762_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s41030-017-0027-5","volume":"3","author":"C Burudpakdee","year":"2017","unstructured":"Burudpakdee C, Seetasith A, Dunne P, et al. A real-world study of 30-day exacerbation outcomes in chronic obstructive pulmonary disease (COPD) patients managed with Aerobika OPEP. Pulm Ther. 2017;3:163\u201371.","journal-title":"Pulm Ther"},{"issue":"1","key":"3762_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s41030-018-0055-9","volume":"4","author":"C Burudpakdee","year":"2018","unstructured":"Burudpakdee C, Near AM, Huang H, Coppolo D, Kushnarev V, Suggett J. A real-world evidence study assessing the impact of adding the Aerobika oscillating positive expiratory pressure device to standard of care upon healthcare resource utilization and costs in post-operative patients. Pulm Ther. 2018;4(1):87\u2013101.","journal-title":"Pulm Ther"},{"key":"3762_CR7","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.2147\/COPD.S143334","volume":"12","author":"S Khoudigian-Sinani","year":"2017","unstructured":"Khoudigian-Sinani S, Kowal S, Suggett JA, Coppolo DP. Cost-effectiveness of the Aerobika* oscillating positive expiratory pressure device in the management of COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2017;12:3065\u201373.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3762_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9176504","author":"NX Thanh","year":"2019","unstructured":"Thanh NX, Jacobs P, Suggett J, McIvor A, Kaplan A. Cost-effectiveness of the Aerobika* oscillating positive expiratory pressure device in the management of chronic obstructive pulmonary disease exacerbations in Canada. Can Respir J. 2019. https:\/\/doi.org\/10.1155\/2019\/9176504.","journal-title":"Can Respir J"},{"issue":"4","key":"3762_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41366-025-01985-1","volume":"50","author":"FH Sert Kuniyoshi","year":"2026","unstructured":"Sert Kuniyoshi FH, Cameron A, P\u00e9pin JL, et al. Adherence to positive airway pressure therapy and healthcare resource utilization and costs among patients with obstructive sleep apnea and obesity. Int J Obes (Lond). 2026;50(4):741\u20139.","journal-title":"Int J Obes (Lond)"},{"key":"3762_CR10","first-page":"232","volume":"22","author":"A Ferguson","year":"2017","unstructured":"Ferguson A, Wright S. Innovative chest physiotherapy techniques (the MetaNeb system) in the intubated child with extensive burns. Respir Med Case Rep. 2017;22:232\u20134.","journal-title":"Respir Med Case Rep"},{"issue":"3","key":"3762_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.chest.2025.08.040","volume":"169","author":"Z Hu","year":"2026","unstructured":"Hu Z, Pu X, Tang R, et al. Effect of continuous high-frequency oscillation therapy on lung aeration in mechanically ventilated patients with impaired consciousness: a multicenter randomized controlled trial. Chest. 2026;169(3):665\u201375.","journal-title":"Chest"},{"issue":"1","key":"3762_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8\u201327.","journal-title":"Med Care"},{"key":"3762_CR13","unstructured":"Centers for Disease Control and Prevention; Agency for Toxic Substances and Disease Registry; Geospatial Research, Analysis, and Services Program. CDC\/ATSDR Social Vulnerability Index 2022 Database, United States [Internet]. Atlanta (GA): CDC\/ATSDR; 2022. https:\/\/www.atsdr.cdc.gov\/placeandhealth\/svi\/data_documentation_download.html. Accessed 2026 Apr 27."},{"key":"3762_CR14","unstructured":"Research Data Assistance Center (ResDAC). CMS cell size suppression policy [Internet]. Minneapolis (MN): ResDAC. https:\/\/resdac.org\/articles\/cms-cell-size-suppression-policy. Accessed 2026 Apr 27."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03762-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03762-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03762-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:42:12Z","timestamp":1789116132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03762-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":14,"alternative-id":["3762"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03762-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"8 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michael Barna is an employee of Mathematica, Inc. Wendy Qi and Suhui Li are former employees of Mathematica, Inc. Jocelyn Klabnik, Gwen Warling, and Stanley Dietz are employed by Baxter. Noah Lechtzin is a consultant with Baxter. Mathematica, Inc was contracted by Baxter to conduct this work. All authors listed do not have any conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Helsinki Declaration. This is a secondary analysis of de-identified data without access to personal identifying information and without direct patient contact or primary data collection. All patient-level and provider-level data within the database contain synthetic identifiers to protect the privacy of patients and data contributors, and all analysis data sets are Health Insurance Portability and Accountability Act (HIPAA) compliant. This study fits within the scope of Mathematica\u2019s DIL data use agreement with CMS, which is exempt from institutional review board (IRB) review. Furthermore, per\u00a045 Code of Federal Regulations (CFR) 46.104 d4, IRB approval is not required for secondary research, which does not use any identifiable information and if the study team does not have the code key with which the information can be made identifiable. This study is therefore not considered human subjects research and exempt from requiring IRB oversight.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}